Venetoclax
- Generic Name
- Venetoclax
- Brand Names
- Venclexta, Venclyxto
- Drug Type
- Small Molecule
- Chemical Formula
- C45H50ClN7O7S
- CAS Number
- 1257044-40-8
- Unique Ingredient Identifier
- N54AIC43PW
- Background
Venetoclax is a BCL-2 inhibitor that was initially approved by the FDA in April 2016 . Proteins in the B cell CLL/lymphoma 2 (BCL-2) family are important regulators of the apoptotic (programmed cell death) process , . Venetoclax is used to treat chronic lymphocytic leukemia (CLL) and certain types of small lymphocytic lymphoma . CLL is the most prevalent leu...
- Indication
本品与阿扎胞苷联合用于治疗因合并症不适合接受强诱导化疗，或者年龄75岁及以上的新诊断的成人急性髓系白血病患者。
- Associated Conditions
- Acute Myeloid Leukemia, Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma
- Associated Therapies
- -
Venetoclax Treatment (26 Cycles) With 6 Cycles or 12 Cycles of Epcoritamab in Patients With Relapsed or Refractory CLL or SLL
- First Posted Date
- 2023-03-30
- Last Posted Date
- 2024-04-12
- Target Recruit Count
- 112
- Registration Number
- NCT05791409
- Locations
- 🇳🇱
NL-Tilburg-ETZ, Tilburg, Netherlands
🇳🇱NL-Alkmaar-NWZ, Alkmaar, Netherlands
🇩🇪DE-Freiburg-UNIKLINIKFREIBURG, Freiburg, Germany
A Proof of Concept Pilot Study of the Addition of Venetoclax to Standard Remission Induction Chemotherapy Fludarabine or Cladrabine, Cytarabine, and Granulocyte Colony Stimulating Factor (G-CSF) (FLAG or CLAG) for Frontline Therapy of Secondary Acute Myeloid Leukemia
- Conditions
- Interventions
- First Posted Date
- 2023-03-23
- Last Posted Date
- 2024-06-21
- Lead Sponsor
- University of Michigan Rogel Cancer Center
- Target Recruit Count
- 20
- Registration Number
- NCT05780879
- Locations
- 🇺🇸
University of Michigan Rogel Cancer Center, Ann Arbor, Michigan, United States
Azacitidine Combined With Venetoclax in Patients With Higher-risk Chronic Myelomonocytic Leukemia (AVENHIR)
- First Posted Date
- 2023-03-14
- Last Posted Date
- 2024-08-02
- Lead Sponsor
- Groupe Francophone des Myelodysplasies
- Target Recruit Count
- 44
- Registration Number
- NCT05768711
- Locations
- 🇫🇷
CHU d'Angers, Angers, France
🇫🇷CHU d'Amiens, Amiens, France
🇫🇷Hôpital Avicenne, Bobigny, France
Trial of Cladribine and Low-Dose Cytarabine (LoDAC) Alternating With Decitabine vs. Hypomethylating Agents (HMA) Plus Venetoclax as Frontline Therapy for AML or High-Grade MDS in Patients Unfit for Intensive Induction
- Conditions
- Interventions
- First Posted Date
- 2023-03-13
- Last Posted Date
- 2024-12-13
- Lead Sponsor
- University of Florida
- Target Recruit Count
- 98
- Registration Number
- NCT05766514
- Locations
- 🇺🇸
University of Florida, Gainesville, Florida, United States
HEM-iSMART-B: Dasatinib + Venetoclax + Dexamethasone + Cyclophosphamide and Cytarabine in Pediatric Patients With Relapsed or Refractory Hematological Malignancies
- Conditions
- Acute Lymphoblastic LeukemiaLymphoblastic Lymphoma (Precursor B-Lymphoblastic Lymphoma/Leukaemia) RecurrentLymphoblastic Lymphoma (Precursor T-Lymphoblastic Lymphoma/Leukaemia) RecurrentLymphoblastic Lymphoma (Precursor T-Lymphoblastic Lymphoma/Leukaemia) RefractoryLymphoblastic Lymphoma (Precursor B-Lymphoblastic Lymphoma/Leukaemia) Refractory
- Interventions
- First Posted Date
- 2023-03-02
- Last Posted Date
- 2024-06-21
- Lead Sponsor
- Princess Maxima Center for Pediatric Oncology
- Target Recruit Count
- 26
- Registration Number
- NCT05751044
- Locations
- 🇳🇱
Princess Máxima Center for Pediatric Oncology, Utrecht, Netherlands
HEM-iSMART-C: Ruxolitinib + Venetoclax + Dexamethasone + Cyclophosphamide and Cytarabine in Pediatric Patients With Relapsed or Refractory Hematological Malignancies
- Conditions
- Acute Lymphoblastic Leukemia, in RelapseLymphoblastic Lymphoma (Precursor B-Lymphoblastic Lymphoma/Leukaemia) RecurrentLymphoblastic Lymphoma (Precursor T-Lymphoblastic Lymphoma/Leukaemia) RefractoryLymphoblastic Lymphoma (Precursor T-Lymphoblastic Lymphoma/Leukaemia) RecurrentLymphoblastic Lymphoma (Precursor B-Lymphoblastic Lymphoma/Leukaemia) Refractory
- Interventions
- First Posted Date
- 2023-02-27
- Last Posted Date
- 2024-06-21
- Lead Sponsor
- Princess Maxima Center for Pediatric Oncology
- Target Recruit Count
- 26
- Registration Number
- NCT05745714
- Locations
- 🇳🇱
Princess Máxima Center for Pediatric Oncology, Utrecht, Netherlands
HEM-iSMART-A: Decitabine / Venetoclax and Navitoclax in Pediatric Patients With Relapsed or Refractory Hematological Malignancies
- Conditions
- Lymphoblastic Lymphoma (Precursor B-Lymphoblastic Lymphoma/Leukaemia) RecurrentAcute Lymphoblastic Leukemia, in RelapseLymphoblastic Lymphoma (Precursor T-Lymphoblastic Lymphoma/Leukaemia) RefractoryLymphoblastic Lymphoma (Precursor T-Lymphoblastic Lymphoma/Leukaemia) RecurrentLymphoblastic Lymphoma (Precursor B-Lymphoblastic Lymphoma/Leukaemia) Refractory
- Interventions
- First Posted Date
- 2023-02-23
- Last Posted Date
- 2024-06-21
- Lead Sponsor
- Princess Maxima Center for Pediatric Oncology
- Registration Number
- NCT05740449
- Locations
- 🇳🇱
Princess Máxima Center for Pediatric Oncology, Utrecht, Netherlands
A Study to Investigate the Safety and Tolerability of Ziftomenib in Combination with Venetoclax/Azacitidine, Venetoclax, or 7+3 in Patients with AML
- Conditions
- Interventions
- First Posted Date
- 2023-02-21
- Last Posted Date
- 2024-10-26
- Lead Sponsor
- Kura Oncology, Inc.
- Target Recruit Count
- 212
- Registration Number
- NCT05735184
- Locations
- 🇺🇸
Moores UC San Diego Cancer Center, La Jolla, California, United States
🇺🇸USC University of Southern California / Norris Comprehensive Cancer Center, Los Angeles, California, United States
🇺🇸UCLA - Bowyer Oncology Center, Los Angeles, California, United States
Adaptive Treatment for Acute Myeloid Leukemia Based on D14 MRD Results
- First Posted Date
- 2023-02-21
- Last Posted Date
- 2023-03-15
- Lead Sponsor
- Shanghai Tong Ren Hospital
- Target Recruit Count
- 58
- Registration Number
- NCT05736978
- Locations
- 🇨🇳
Pla Navy Feature Medical Center, Shanghai, China
🇨🇳Shanghai Ruijin Hospital, Shanghai, China
🇨🇳Shanghai Tong Ren hospital, Shanghai, China
Pirtobrutinib and Venetoclax in Waldenström Macroglobulinemia
- Conditions
- Interventions
- First Posted Date
- 2023-02-21
- Last Posted Date
- 2024-11-08
- Lead Sponsor
- Dana-Farber Cancer Institute
- Target Recruit Count
- 42
- Registration Number
- NCT05734495
- Locations
- 🇺🇸
Beth Israel Deaconness Medical, Boston, Massachusetts, United States
🇺🇸Dana Farber Cancer Institute, Boston, Massachusetts, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.